Catalyst Pharmaceuticals (NASDAQ:CPRX) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a hold rating in a research report released on Saturday morning.

A number of other equities research analysts also recently weighed in on CPRX. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Finally, Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.17.

Catalyst Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:CPRX opened at $31.15 on Friday. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The firm has a 50-day simple moving average of $25.31 and a 200 day simple moving average of $23.93. The company has a market cap of $3.81 billion, a PE ratio of 18.43, a P/E/G ratio of 1.01 and a beta of 0.72.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 474 shares in the last quarter. Convergence Investment Partners LLC lifted its position in shares of Catalyst Pharmaceuticals by 106.8% in the 1st quarter. Convergence Investment Partners LLC now owns 75,682 shares of the biopharmaceutical company’s stock valued at $1,874,000 after acquiring an additional 39,092 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at approximately $257,000. Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after buying an additional 433,318 shares in the last quarter. Finally, AlphaCentric Advisors LLC lifted its position in Catalyst Pharmaceuticals by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 23,286 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 1,266 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Key Stories Impacting Catalyst Pharmaceuticals

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).